7. Abbott Laboratories (NYSE:ABT)
Abbott Laboratories (NYSE: ABT) occupies seventh place because it provides a more diversified healthcare investment than a conventional drug manufacturer. The company operates across medical devices, diabetes technology, diagnostic testing, nutritional products and branded generic medicines. That diversity reduces dependence on any single blockbuster treatment or clinical trial. While a biotechnology company may rise or fall based on one experimental medicine, Abbott Laboratories (NYSE: ABT) generates revenue from products used across hospitals, laboratories, clinics and homes. This makes the company one of the more dependable healthcare stocks for investors who prioritize stability.
The company reported second-quarter 2026 sales growth of 13% on a reported basis and 4.8% on a comparable basis. Adjusted diluted earnings reached $1.31 per share, and management raised its full-year adjusted earnings guidance to between $5.45 and $5.60 per share. Abbott Laboratories (NYSE: ABT) also reaffirmed its expectation for comparable annual sales growth of between 6.5% and 7.5%. The gap between reported and comparable growth partly reflects the March 2026 acquisition of Exact Sciences, which expanded Abbott’s position in cancer diagnostics. The deal gives the company another meaningful growth platform at a time when early cancer detection and noninvasive testing are becoming increasingly important parts of modern healthcare.
Diabetes technology remains one of the company’s most recognizable opportunities. Abbott Laboratories (NYSE: ABT) secured European approval for Libre Duo, which the company describes as the first wearable sensor capable of monitoring both glucose and ketone levels. The company is also advancing cardiovascular technologies, including an investigational system designed to treat severe calcium buildup in coronary arteries before stent placement. These products may not create the type of overnight stock-price movement associated with a successful obesity-drug trial, but they can produce recurring demand and long commercial lifecycles. Abbott Laboratories (NYSE: ABT) ranks above the slower-growing companies because of its raised 2026 earnings outlook, diversified operations and exposure to diabetes care, diagnostics and minimally invasive medical technology. It ranks below the leading pharmaceutical stocks because its growth profile is steadier rather than explosive.
Click next to see the following stock...
